Antibody–drug conjugates at Antibody Engineering 2026
Dec 13–16, 2026 San Diego, CA ~900 attendees Website
14 organizations at Antibody Engineering 2026 present work in adcs & conjugates: 6 drug developers, 5 suppliers and service providers and 3 academic, government and non-profit bodies. Between them they bring 17 presentations to the program. Most represented: AstraZeneca (3 on the program), City of Hope (2 on the program), Invenra (1 on the program). As of Nov 10, 2026.
Format
Top represented
Showing 1–14 of 14 organizations
| Organization | Antibody Engineering 2026 Attendance |
|---|---|
AstraZeneca Cambridge, United Kingdom | |
Global pharmaceutical company developing antibodies, antibody-drug conjugates and multispecifics in oncology and other diseases. | Talk Sun Dec 13 11:00am–11:45am Keynote Mon Dec 14 10:20am–10:55am From Insight to Impact: Translational Medicine as a Driver of ADC Clinical Success and Future Innovation Why finding biological markers of response early helps antibodies carrying a cell-killing drug succeed in patients. ADCs & conjugates Talk Wed Dec 16 10:30am–11:00am CD8-Guided T Cell Engager with Potent Preclinical Efficacy and Superior Therapeutic Index An antibody that pulls killer T cells onto liver cancer cells while rousing fewer of the T cells that drive dangerous immune reactions. Chair Wed Dec 16 2:10pm–2:15pm Talk Wed Dec 16 2:15pm–2:45pm |
City of Hope Duarte, CA | |
Cancer research and treatment center with a graduate school. | Talk Wed Dec 16 4:15pm–4:45pm MPACT: Engineering the Fc–FcγR Interface for Plug-and-Play, Mixed-Valency Multispecific Antibodies Using a chemical bond at a natural antibody contact point to snap extra targeting or immune-activating parts onto one antibody. Bispecifics & multispecifics Talk Wed Dec 16 4:15pm–4:45pm Turning up the Heat: Radioimmunoconjugates for Targeted Radiation Therapy Using antibodies and smaller antibody pieces to carry radioactive atoms that both image and irradiate tumors. |
Invenra Madison, WI | |
Antibody discovery company offering its B-Body bispecific and T-Body trispecific platforms to partners, including for multispecific antibody-drug conjugates. | Booth Exhibiting at Booth 108 Mon, Dec 144:00pm–4:45pmTue, Dec 159:45am–4:45pm Talk Mon Dec 14 12:15pm–1:15pm From Bi- to Trispecific Antibodies: Reimagining the Next Generation of ADCs Antibodies that carry a cell-killing drug and bind several tumor targets, so tumors cannot escape by losing just one. ADCs & conjugatesBispecifics & multispecifics |
WuXi Biologics Wuxi, China | |
Contract research, development and manufacturing organization for biologics, including antibodies, bispecifics and antibody–drug conjugates. | Booth Exhibiting at Booth 208 Mon, Dec 144:00pm–4:45pmTue, Dec 159:45am–4:45pm Talk Mon Dec 14 1:15pm–1:45pm Bispecific Antibody Discovery: Practical Strategies from MOA to Preclinical Candidates Practical steps for taking two-target antibodies from a chosen mechanism to preclinical candidates, with case studies on design, screening and testing. Bispecifics & multispecificsAntibody discovery |
Hummingbird Bioscience Singapore | |
Develops antibody therapeutics and antibody-drug conjugates for cancer and autoimmune diseases. | Talk Wed Dec 16 5:15pm–5:45pm Novel, Next-generation ADCs for Autoimmune and Inflammatory Diseases How antibodies carrying a drug payload could be aimed at the immune cells driving inflammation, not just at cancer. Beyond oncology |
Memorial Sloan Kettering Cancer Center New York, NY | |
Cancer treatment and research center in New York City. | Talk Wed Dec 16 3:15pm–3:45pm DLL3 Antibody-Based Radiotheranostics: From ImmunoPET to Targeted Radioligand Therapy Antibodies carrying radioactive tags to both image and treat neuroendocrine tumors, and to pick the patients likely to respond. |
Merck Rahway, NJ | |
Global pharmaceutical company, known as MSD outside the US and Canada, developing medicines, vaccines and biologics. | Talk Wed Dec 16 4:45pm–5:15pm uPAR Targeting Cytotoxic Antibody Drug Conjugates Selectively Deplete Proinflammatory Myeloid Cells for Autoimmune Indications Using single-cell data to pick a marker on inflammatory immune cells in rheumatoid arthritis, then killing those cells with a drug-carrying antibody. Beyond oncology |
Develops pH-responsive polymer nanoparticles that release drugs in the acidic tumor environment, including the MMAE conjugate ONM-421. | Talk Wed Dec 16 2:45pm–3:15pm Antigen-Independent Antitumor Activity of ONM-421, a pH-Responsive Polymer–Drug Conjugate Delivering MMAE to Solid Tumors A polymer that releases its chemotherapy payload in the acidic environment around tumors, working without needing a tumor marker to bind. |
Tacalyx Berlin, Germany | |
Max Planck spin-out developing antibodies and antibody–drug conjugates against tumor-associated carbohydrate antigens. | Talk Tue Dec 15 11:00am–11:30am High Co-crosslinking of Surface Proteins by Anti-carbohydrate Antibodies for Rapid Internalization and Efficient Payload Delivery Antibodies against tumor sugar structures that clump many surface proteins together, so cells swallow them fast and take up a drug payload. ADCs & conjugates |
Trio Pharmaceuticals San Diego, CA | |
Develops bispecific antibodies and bispecific antibody–drug conjugates that target both cancer cells and immunosuppressive cells in tumors. | Talk Wed Dec 16 11:00am–11:30am TIE-ADC™: A Bispecific ADC Platform Eliminating Cancer Cells and Tumor Immunosuppressor Cells to Enhance Anti-Tumor Immunity A drug-carrying antibody that binds both a tumor marker and a marker on immune-suppressing cells, killing both with one payload. ADCs & conjugates |
Washington University School of Medicine St. Louis, MO | |
Medical school of Washington University in St. Louis. | Chair Wed Dec 16 2:10pm–2:15pm |
Lonza Basel, Switzerland | |
Contract development and manufacturing organization for biologics, including antibodies and bioconjugates. | Booth Exhibiting at Booth T10 Mon, Dec 144:00pm–4:45pmTue, Dec 159:45am–4:45pm Talk Tue Dec 15 12:35pm–1:05pm Lonza Scientific Briefing Developability & CMC |
Ajinomoto Tokyo, Japan | |
Japanese food and amino-acid group whose Bio-Pharma Services arm is a contract developer and manufacturer of drugs, antibody–drug conjugates among them. | Booth Exhibiting at Booth K1 Mon, Dec 144:00pm–4:45pmTue, Dec 159:45am–4:45pm |
NJ Bio Princeton, NJ | |
Contract research and manufacturing organization specializing in antibody–drug conjugates, bioconjugation and linker-payload chemistry, from discovery through GMP manufacturing. | Booth Exhibiting at Booth 509 Mon, Dec 144:00pm–4:45pmTue, Dec 159:45am–4:45pm |
Find buyers in adcs & conjugates
Tell us what you sell and we’ll find the people at organizations working on adcs & conjugates most likely to buy it.
- Who to contact
- Their contact info
- What to say
- Free, no sign-up
Browse Antibody Engineering 2026 by
Organization type
Topic
Exhibit hall
Everyone
Not affiliated with or endorsed by Antibody Engineering & Therapeutics, its organizers or The Antibody Society. Submit a correction